MedTrace Logo

Identifying an Ideal Cardiopulmonary Exercise Test Parameter

NCT01162083 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-02-17

No results posted yet for this study

Summary

Cardiopulmonary exercise testing (CPET) is a safe, noninvasive investigation where a patient walks on a treadmill or cycles whilst attached to an ECG and with a mask that measures the air breathed in and out. It has numerous clinical uses, such as diagnosing the main cause in patients with breathlessness, deciding on timing for heart transplantation and assessing whether patients are safe for a general anaesthetic.

A patient's peak oxygen consumption, the maximum amount of oxygen taken up by the blood from the lungs when breathing increases during exercise, is the main measurement taken from CPET. It is low in heart disease and has been used to predict the risk of death and therefore plan treatments for patients. However this is also low in numerous other diseases including lung disease; reduced oxygen consumption in patients with two conditions may be wrongly thought to be because of the heart leading to inappropriate action and distress to the patient.

Newer measurements of exercise capacity from the same exercise test are better at predicting death in heart failure.

We propose that they are more specific for heart failure over other diseases, for example lung disease, when compared with peak oxygen consumption, and are superior when a single best test for heart failure is required.

This research aims to identify which measurement of exercise capacity is most specific for heart failure. We will perform the test on many patients with different diseases, and before and after procedures such as the implantation of special pacemakers, and heart valve operations. This should lead to a more accepted use of this investigation and the more appropriate identification of which patient should have which procedure.

Conditions

  • Left Ventricular Systolic Dysfunction
  • Mitral Regurgitation

Sponsors & Collaborators

  • Humboldt-Universität zu Berlin

    collaborator OTHER

  • British Heart Foundation

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Roland Wensel, MD PhD · Imperial College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01162083 on ClinicalTrials.gov